DrugPatentWatch Database Preview

ZURAMPIC Drug Profile

  Purchase this report

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Zurampic patents expire, and when can generic versions of Zurampic launch?

Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and seventy-five patent family members in thirty-eight countries.

The generic ingredient in ZURAMPIC is lesinurad. Two suppliers are listed for this compound. Additional details are available on the lesinurad profile page.

Summary for ZURAMPIC

International Patents:	175
US Patents:	8
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	48
Patent Applications:	52
Drug Prices:	Drug price information for ZURAMPIC
DailyMed Link:	ZURAMPIC at DailyMed

Generic Entry Opportunity Date for ZURAMPIC

NDA:

207988

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZURAMPIC

Drug Class	Urate Transporter 1 Inhibitor
Mechanism of Action	Urate Transporter 1 Inhibitors Cytochrome P450 3A Inducers

Synonyms for ZURAMPIC

(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid

{[5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-1,2,4-TRIAZOL-3-YL]SULFANYL}ACETIC ACID

{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid

09ERP08I3W

2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid

2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid

2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid

2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-acetic acid

2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid

2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid

2-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid

3777AH

878672-00-5

Acetic acid, 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)-

Acetic acid,[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-

ACN-050764

AK323774

AKOS027327368

C17H14BrN3O2S

CHEBI:90929

CHEMBL2105720

CS-1389

D09921

D0C3SW

DB11560

EX-A1289

FGQFOYHRJSUHMR-UHFFFAOYSA-N

GTPL7673

HE067018

HY-15258

KB-78121

KS-00000LAE

LESINURAD

Lesinurad (RDEA-594)

Lesinurad (RDEA594 pound(c)

Lesinurad (RDEA594)

Lesinurad (USAN)

Lesinurad [USAN:INN]

Lesinurad, >=98% (HPLC)

MFCD22572730

MolPort-039-138-666

RDEA 594

RDEA-594

RDEA594

s4640

SC-94287

SCHEMBL842962

UNII-09ERP08I3W

W-5949

ZINC84757007

Zurampic (TN)

US Patents and Regulatory Information for ZURAMPIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		RX	Yes	Yes
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		RX	Yes	Yes
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		RX	Yes	Yes			Y
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		RX	Yes	Yes
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		RX	Yes	Yes

  Purchase this report

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for ZURAMPIC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,481,581	S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase
7,435,752	N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors
8,552,043	N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors
8,242,154	Compounds, compositions and methods of using same for modulating uric acid levels
7,947,721	S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase

  Purchase this report

see a sample report or, see our see our flat-rate plans

International Patents for ZURAMPIC

Country	Document Number	Estimated Expiration
Cyprus	1116286
Luxembourg	93169
World Intellectual Property Organization (WIPO)	2011159732
Hungary	S1600034
Spain	2513390

Supplementary Protection Certificates for ZURAMPIC

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2016024	Lithuania		PRODUCT NAME: LESINURADAS; REGISTRATION NO/DATE: EU/1/15/1080 20160218
2016000060	Germany		PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 20160218
2016 00034	Denmark		PRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
/2016	Austria		PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222
16/033	Ireland		PRODUCT NAME: (I)PRODUCT (I.E. ACTIVE INGREDIENT OR COMBINATION OF ACTIVE INGREDIENTS) FOR WHICH A CERTIFICATE IS REQUESTED:-LESINURAD, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/15/1080 20160218